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Abstract
1- Oncogenes express proteins of “Tyrosine kinase receptor pathways”, a receptor family including insulin or IGF-
Growth Hormone receptors. Other oncogenes alter the PP2A phosphatase brake over these kinases.
2- Experiments on pancreatectomized animals; treated with pure insulin or total pancreatic extracts, showed that
choline in the extract, preserved them from hepatomas.
Since choline is a methyle donor, and since methylation regulates PP2A, the choline protection may result from
PP2A methylation, which then attenuates kinases.
3- Moreover, kinases activated by the boosted signaling pathway inactivate pyruvate kinase and pyruvate
dehydrogenase. In addition, demethylated PP2A would no longer dephosphorylate these enzymes. A “bottleneck”
between glycolysis and the oxidative-citrate cycle interrupts the glycolytic pyruvate supply now provided via
proteolysis and alanine transamination. This pyruvate forms lactate (Warburg effect) and NAD+ for glycolysis.
Lipolysis and fatty acids provide acetyl CoA; the citrate condensation increases, unusual oxaloacetate sources are
available. ATP citrate lyase follows, supporting aberrant transaminations with glutaminolysis and tumor lipogenesis.
Truncated urea cycles, increased polyamine synthesis, consume the methyl donor SAM favoring carcinogenesis.
4- The decrease of butyrate, a histone deacetylase inhibitor, elicits epigenic changes (PETEN, P53, IGFBP decrease;
hexokinase, fetal-genes-M2, increase)
5- IGFBP stops binding the IGF - IGFR complex, it is perhaps no longer inherited by a single mitotic daughter cell;
leading to two daughter cells with a mitotic capability.
6- An excess of IGF induces a decrease of the major histocompatibility complex MHC1, Natural killer lymphocytes
should eliminate such cells that start the tumor, unless the fever prostaglandin PGE2 or inflammation, inhibit them...
Introduction
The metabolic network of biochemical pathways forms a
system controlled by a few switches, changing the final-
ity of this system. Specific substrates and hormones con-
trol such switches. If for example, glycemia is elevated,
the pancreas releases insulin, activating anabolism and
oxidative glycolysis, energy being required to form new
substance or refill stores. If starvation decreases glyce-
mia, glucagon and epinephrine activate gluconeogenesis
and ketogenesis to form nutriments, mobilizing body
stores. The different finalities of the system are or
oriented by switches sensing the NADH/NAD+, the
ATP/AMP, the cAMP/AMP ratios or the O2 supply...
We will not describe here these metabolic finalities and
their controls found in biochemistry books.
Many of the switches depend of the phosphorylation
of key enzymes that are active or not. Evidently, there is
some coordination closing or opening the different path-
ways. Take for example gluconeogenesis, the citrate con-
densation slows down, sparing OAA, which starts the
gluconeogenic pathway. In parallel, one also has to close
pyruvate kinase (PK); if not, phosphoenolpyruvate would
give back pyruvate, interrupting the pathway. Hence, the
properties of key enzymes acting like switches on the
pathway specify the finality of the system. Our aim is to
show that tumor cells invent a new specific finality, with
mixed glycolysis and gluconeogenesis features. This very
special metabolism gives to tumor cells a selective
advantage over normal cells, helping the tumor to
develop at the detriment of the rest of the body.
I Abnormal metabolism of tumors, a selective
advantage
The initial observation of Warburg 1956 on tumor gly-
colysis with lactate production is still a crucial observa-
tion [1]. Two fundamental findings complete the
metabolic picture: the discovery of the M2 pyruvate
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tyrosine kinase signals and subsequent phosphorylations
in the M2 PK blockade [3-5].
A typical feature of tumor cells is a glycolysis asso-
ciated to an inhibition of apoptosis. Tumors over-
express the high affinity hexokinase 2, which strongly
interacts with the mitochondrial ANT-VDAC-PTP com-
plex. In this position, close to the ATP/ADP exchanger
(ANT), the hexokinase receives efficiently its ATP sub-
strate [6,7]. As long as hexokinase occupies this mito-
chondria site, glycolysis is efficient. However, this has
another consequence, hexokinase pushes away from the
mitochondria site the permeability transition pore
(PTP), which inhibits the release of cytochrome C, the
apoptotic trigger [8]. The site also contains a voltage
dependent anion channel (VDAC) and other proteins.
The repulsion of PTP by hexokinase would reduce the
pore size and the release of cytochrome C. Thus, the
apoptosome-caspase proteolytic structure does not
assemble in the cytoplasm. The liver hexokinase or glu-
cokinase, is different it has less interaction with the site,
has a lower affinity for glucose; because of this differ-
ence, glucose goes preferentially to the brain.
Further, phosphofructokinase gives fructose 1-6 bis
phosphate; glycolysis is stimulated if an allosteric analo-
gue, fructose 2-6 bis phosphate increases in response to
a decrease of cAMP. The activation of insulin receptors
in tumors has multiple effects, among them; a decrease
of cAMP, which will stimulate glycolysis.
Another control point is glyceraldehyde P dehydro-
genase that requires NAD+ in the glycolytic direction. If
the oxygen supply is normal, the mitochondria malate/
aspartate (MAL/ASP) shuttle forms the required NAD+
in the cytosol and NADH in the mitochondria. In
hypoxic conditions, the NAD+ will essentially come via
lactate dehydrogenase converting pyruvate into lactate.
This reaction is prominent in tumor cells; it is the first
discovery of Warburg on cancer.
At the last step of glycolysis, pyruvate kinase (PK) con-
verts phosphoenolpyruvate (PEP) into pyruvate, which
enters in the mitochondria as acetyl CoA, starting the
citric acid cycle and oxidative metabolism. To explain the
PK situation in tumors we must recall that PK only
works in the glycolytic direction, from PEP to pyruvate,
which implies that gluconeogenesis uses other enzymes
for converting pyruvate into PEP. In starvation, when
cells need glucose, one switches from glycolysis to gluco-
neogenesis and ketogenesis; PK and pyruvate dehydro-
genase (PDH) are off, in a phosphorylated form,
presumably following a cAMP-glucagon-adrenergic sig-
nal. In parallel, pyruvate carboxylase (Pcarb) becomes
active. Moreover, in starvation, much alanine comes
from muscle protein proteolysis, and is transaminated
into pyruvate. Pyruvate carboxylase first converts
pyruvate to OAA and then, PEP carboxykinase converts
OAA to PEP etc..., until glucose. The inhibition of PK is
necessary, if not one would go back to pyruvate. Phos-
phorylation of PK, and alanine, inhibit the enzyme.
Well, tumors have a PK and a PDH inhibited by phos-
phorylation and alanine, like for gluconeogenesis, in
spite of an increased glycolysis! Moreover, in tumors,
one finds a particular PK, the M2 embryonic enzyme
[2,9,10] the dimeric, phosphorylated form is inactive,
leading to a “bottleneck “.T h eM 2P Kh a st ob ea c t i -
v a t e db yf r u c t o s e1 - 6b i sPi t sa l l o s t e r i ca c t i v a t o r ,
whereas the M1 adult enzyme is a constitutive active
form. The M2 PK bottleneck between glycolysis and the
citric acid cycle is a typical feature of tumor cell
glycolysis.
We also know that starvation mobilizes lipid stores
from adipocyte to form ketone bodies, they are like glu-
cose, nutriments for cells. Growth hormone, cAMP,
AMP, activate a lipase, which provides fatty acids; their
b oxidation cuts them into acetyl CoA in mitochondria
and in peroxisomes for very long fatty acids; forming
ketone bodies. Normally, citrate synthase slows down, to
spare acetyl CoA for the ketogenic route, and OAA for
the gluconeogenic pathway. Like for starvation, tumors
mobilize lipid stores. But here, citrate synthase activity
is elevated, condensing acetyl CoA and OAA [11-13];
citrate increases, ketone bodies decrease. Consequently,
ketone bodies will stop stimulating Pcarb. In tumors,
the OAA needed for citrate synthase will presumably
come from PEP, via reversible PEP carboxykinase or
other sources. The quiescent Pcarb will not process the
pyruvate produced by alanine transamination after pro-
teolysis, leaving even more pyruvate to lactate dehydro-
genase, increasing the lactate released by the tumor, and
the NAD+ required for glycolysis. Above the bottleneck,
the massive entry of glucose accumulates PEP, which
converts to OAA via mitochondria PEP carboxykinase,
an enzyme requiring biotine-CO2-GDP. This source of
OAA is abnormal, since Pcarb, another biotin-requiring
enzyme, should have provided OAA. Tumors may
indeed contain “morule inclusions” of biotin-enzyme
[14] suggesting an inhibition of Pcarb, presumably a
consequence of the maintained citrate synthase activity,
and decrease of ketone bodies that normally stimulate
Pcarb. The OAA coming via PEP carboxykinase and
OAA coming from aspartate transamination or via
malate dehydrogenase condenses with acetyl CoA, feed-
ing the elevated tumoral citric acid condensation start-
ing the Krebs cycle. Thus, tumors have to find large
amounts of acetyl CoA for their condensation reaction;
it comes essentially from lipolysis and b oxidation of
fatty acids, and enters in the mitochondria via the carni-
tine transporter. This is the major source of acetyl CoA;
since PDH that might have provided acetyl CoA remains
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The blockade of PDH [15] was recently reversed by
inhibiting its kinase [16,17]. The key question is then to
find out why NADH, a natural citrate synthase inhibitor
did not switch off the enzyme in tumor cells. Probably,
the synthesis of NADH by the dehydrogenases of the
Krebs cycle and malate/aspartate shuttle, was too low,
or the oxidation of NADH via the respiratory electron
transport chain and mitochondrial complex1 (NADH
dehydrogenase) was abnormally elevated. Another
important point concerns PDH and a ketoglutarate
dehydrogenase that are homologous enzymes, they
might be regulated in a concerted way; when PDH is
off, a ketoglutarate dehydrogenase might be also be slo-
wed. Moreover, this could be associated to an upstream
inhibition of aconinase by NO, or more probably to a
blockade of isocitrate dehydrogenase, which favors in
tumor cells, the citrate efflux from mitochondria, and
the ATP citrate lyase route. Normally, an increase of
NADH inhibits the citrate condensation, favoring the
ketogenic route associated to gluconeogenesis, which
turns off glycolysis. Apparently, this regulation does not
occur in tumors, since citrate synthase remains active.
Moreover, in tumor cells, the a ketoglutarate not pro-
cessed by a ketoglutarate dehydrogenase converts to
glutamate, via glutamate dehydrogenase, in this direction
the reaction forms NAD+, backing up the LDH produc-
tion. Other sources of glutamate are glutaminolysis,
which increases in tumors [2].
The Figure 1 shows how tumors bypass the PK and
PDH bottlenecks and evidently, the increase of glucose
influx above the bottleneck, favors the supply of sub-
strates to the pentose shunt, as pentose is needed for
synthesizing ribonucleotides, RNA and DNA. The Figure
1 represents the stop below the citrate condensation.
H e n c e ,c i t r a t eq u i t st h em i t o c h o n d r i at og i v ev i aA T P
citrate lyase, acetyl CoA and OAA in the cytosol of
tumor cells. Acetyl CoA supports the synthesis of fatty
acids and the formation of triglycerides. The other pro-
duct of the ATP citrate lyase reaction, OAA, drives the
transaminase cascade (ALAT and GOT transaminases)
in a direction that consumes GLU and glutamine and
converts in fine alanine into pyruvate and lactate plus
NAD+. This consumes protein body stores that provide
amino acids and much alanine (like in starvation). The
Figure 1 indicates that malate dehydrogenase is a source
of NAD+ converting OAA into malate, which backs-up
L D H .P a r to ft h em a l a t ec o n v e r t st op y r u v a t e( m a l i c
enzyme) and processed by LDH. Moreover, malate
enters in mitochondria via the shuttle and gives back
OAA to feed the citrate condensation. Glutamine will
also provide amino groups for the “de novo” synthesis
of purine and pyrimidine bases particularly needed by
tumor cells. The Figure 1 indicates that ASP shuttled
out of the mitochondrial, joins the ASP formed by cyto-
solic transaminases, to feed the synthesis of pyrimidine
bases via ASP transcarbamylase, a process also enhanced
in tumor cells. In tumors, this silences the argininosuc-
cinate synthetase step of the urea cycle [18-20]. This
blockade also limits the supply of fumarate to the Krebs
cycle. The latter, utilizes the a ketoglutarate provided by
the transaminase reaction, since a ketoglutarate coming
via aconitase slows down. Indeed, NO and peroxynitrite
increase in tumors and probably block aconitase. The
Figure 1 indicates the cleavage of arginine into urea and
ornithine. In tumors, the ornithine production increases,
following the polyamine pathway. Ornithine is decar-
boxylated into putrescine by ornithine decarboxylase,
then it captures the backbone of S adenosyl methionine
(SAM) to form polyamines spermine then spermidine,
the enzyme controlling the process is SAM decarboxy-
lase. The other reaction product, 5-methlthioribose is
then decomposed into methylthioribose and adenine,
p r o v i d i n gp u r i n eb a s e st ot h et u m o r .W es h a l la n a l y z e
below the role of SAM in the carcinogenic mechanism,
its destruction aggravates the process.
In summary, it is like if the mechanism switching
from gluconeogenesis to glycolysis was jammed in
tumors, PK and PDH are at rest, like for gluconeogen-
esis, but citrate synthase is on. Thus, citric acid conden-
sation pulls the glucose flux in the glycolytic direction,
which needs NAD+; it will come from the pyruvate to
lactate conversion by lactate dehydrogenase (LDH) no
longer in competition with a quiescent Pcarb. Since the
citrate condensation consumes acetyl CoA, ketone
bodies do not form; while citrate will support the synth-
esis of triglycerides via ATP citrate lyase and fatty acid
synthesis... The cytosolic OAA drives the transaminases
in a direction consuming amino acid. The result of
these metabolic changes is that tumors burn glucose
while consuming muscle protein and lipid stores of the
organism. In a normal physiological situation, one mobi-
lizes stores for making glucose or ketone bodies, but not
while burning glucose! Tumor cell metabolism gives
them a selective advantage over normal cells. However,
one may attack some vulnerable points.
II Starters for cancer metabolic anomaly
1. Lessons from oncogenes
Following the discovery of Rous sarcoma virus trans-
mitting cancer [21], we have to wait the work of Stehe-
lin [22] to realize that this retrovirus only transmitted
a gene captured from a previous host. When one finds
that the transmitted gene encodes the Src tyrosine
kinase, we are back again to the tyrosine kinase signals,
similar to those activated by insulin or IGF, which
control carbohydrate metabolism, anabolism and
mitosis.
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control causes tumors. However, the captured viral
oncogene (v-oncogene) derives from a normal host gene
the proto-oncogene. The virus only perturbs the expres-
sion of a cellular gene the proto-oncogene. It may mod-
ify its expression, or its regulation, or transmit a
mutated form of the proto-oncogene. Independently of
any viral infection, a similar tumorigenic process takes
place, if the proto-oncogene is translocated in another
chromosome; and transcribed under the control of
stronger promoters. In this case, the proto-oncogene
becomes an oncogene of cellular origin (c-oncogene).
Figure 1 Cancer metabolism. Glycolysis is elevated in tumors, but a pyruvate kinase (PK) “bottleneck” interrupts phosphoenol pyruvate (PEP) to
pyruvate conversion. Thus, alanine following muscle proteolysis transaminates to pyruvate, feeding lactate dehydrogenase, converting pyruvate
to lactate, (Warburg effect) and NAD+ required for glycolysis. Cytosolic malate dehydrogenase also provides NAD+ (in OAA to MAL direction).
Malate moves through the shuttle giving back OAA in the mitochondria. Below the PK-bottleneck, pyruvate dehydrogenase (PDH) is
phosphorylated (second bottleneck). However, citrate condensation increases: acetyl-CoA, will thus come from fatty acids b-oxydation and
lipolysis, while OAA sources are via PEP carboxy kinase, and malate dehydrogenase, (pyruvate carboxylase is inactive). Citrate quits the
mitochondria, (note interrupted Krebs cycle). In the cytosol, ATPcitrate lyase cleaves citrate into acetyl CoA and OAA. Acetyl CoA will make fatty
acids-triglycerides. Above all, OAA pushes transaminases in a direction usually associated to gluconeogenesis! This consumes protein stores,
providing alanine (ALA); like glutamine, it is essential for tumors. The transaminases output is aspartate (ASP) it joins with ASP from the shuttle
and feeds ASP transcarbamylase, starting pyrimidine synthesis. ASP in not processed by argininosuccinate synthetase, which is blocked,
interrupting the urea cycle. Arginine gives ornithine via arginase, ornithine is decarboxylated into putrescine by ornithine decarboxylase.
Putrescine and SAM form polyamines (spermine spermidine) via SAM decarboxylase. The other product 5-methylthioadenosine provides adenine.
Arginine deprivation should affect tumors. The SAM destruction impairs methylations, particularly of PP2A, removing the “signaling kinase brake”,
PP2A also fails to dephosphorylate PK and PDH, forming the “bottlenecks”. (Black arrows = interrupted pathways).
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oncogene occurs if a retrovirus simply inserts its strong
promoters in front of the proto-oncogene enhancing its
expression.
It is impressive to find that retroviral oncogenes and
cellular oncogenes disturb this major signaling pathway:
the MAP kinases mitogenic pathways. At the ligand
level we find tumors such Wilm’s kidney cancer, result-
ing from an increased expression of insulin like growth
factor; we have also the erbB or V-int-2 oncogenes
expressing respectively NGF and FGF growth factor
receptors. The receptors for these ligands activate tyro-
sine kinase signals, similarly to insulin receptors. The
Rous sarcoma virus transmits the src tyrosine kinase,
which activates these signals, leading to a chicken leuke-
mia. Similarly, in murine leukemia, a virus captures and
retransmits the tyrosine kinase abl. Moreover, abl is also
stimulated if translocated and expressed with the bcr
gene of chromosome 22, as a fusion protein (Philadel-
phia chromosome). Further, ahead Ras exchanging pro-
tein for GTP/GDP, and then the Raf serine-threonine
kinases proto-oncogenes are known targets for onco-
genes. Finally, at the level of transcription factors acti-
vated by MAP kinases, one finds cjun, cfos or cmyc. An
avian leucosis virus stimulates cmyc, by inserting its
strong viral promoter. The retroviral attacks boost the
mitogenic MAP kinases similarly to inflammatory cyto-
kins, or to insulin signals, that control glucose transport
and gycolysis.
In addition to the MAP kinase mitogenic pathway, tyr-
osine kinase receptors activate PI3 kinase pathways;
PTEN phosphatase counteracts this effect, thus acting as
a tumor suppressor. Recall that a DNA virus, the
Epstein-Barr virus of infectious mononucleose, gives
also the Burkitt lymphoma; the effect of the virus is to
enhance PI3 kinase. Down stream, we find mTOR (the
target of rapamycine, an immune-suppressor) mTOR,
inhibits PP2A phosphatase, which is also a target for the
simian SV40 and Polyoma viruses. Schematically, one
may consider that the different steps of MAP kinase
pathways are targets for retroviruses, while the different
steps of PI3 kinase pathway are targets for DNA viruses.
The viral-driven enhanced function of these pathways
mimics the effects of their prolonged activation by their
usual triggers, such as insulin or IGF; one then expects
to find an associated increase of glycolysis. The insulin
or IGF actions boost the cellular influx of glucose and
glycolysis. However, if the signaling pathway gets out of
control, the tyrosine kinase phosphorylations may lead
to a parallel PK blockade [3-5] explaining the tumor
bottleneck at the end of glycolysis. Since an activation
of enyme kinases may indeed block essential enzymes
(PK, PDH and others); in principle, the inactivation of
phosphatases may also keep these enzymes in a
phosphorylated form and lead to a similar bottleneck
a n dw ed ok n o wt h a to n c o g e n e sb i n da n da f f e c tP P 2 A
phosphatase. In sum, a perturbed MAP kinase pathway,
elicits metabolic features that would give to tumor cells
their metabolic advantage.
2. The methylation hypothesis and the role of PP2A
phosphatase
I nar e m a r k a b l ec o m m e n t ,N e w b e r n e[ 2 3 ]h i g h l i g h t s
interesting observations on the carcinogenicity of dietha-
nolamine [24] showing that diethanolamine decreased
choline derivatives and methyl donors in the liver, like
does a choline deficient diet. Such conditions trigger
tumors in mice, particularly in the B6C3F1 strain.
Again, the historical perspective recalled by Newberne’s
comment brings us back to insulin. Indeed, after the
discovery of insulin in 1922, Banting and Best were able
to keep alive for several months depancreatized dogs,
treated with pure insulin. However, these dogs devel-
oped a fatty liver and died. Unlike pure insulin, the total
pancreatic extract contained a substance that prevented
fatty liver: a lipotropic substance identified later as being
choline [25]. Like other lipotropes, (methionine, folate,
B12) choline supports transmethylation reactions, of a
variety of substrates, that would change their cellular
fate, or action, after methylation. In the particular case
concerned here, the removal of triglycerides from the
liver, as very low-density lipoprotein particles (VLDL),
requires the synthesis of lecithin, which might decrease
if choline and S-adenosyl methionine (SAM) are miss-
ing. Hence, a choline deficient diet decreases the
removal of triglycerides from the liver; a fatty liver and
tumors may then form. In sum, we have seen that path-
ways exemplified by the insulin-tyrosine kinase signaling
pathway, which control anabolic processes, mitosis,
growth and cell death, are at each step targets for onco-
genes; we now find that insulin may also provoke fatty
liver and cancer, when choline is not associated to insu-
lin. We must now find how the lipotropic methyl donor
controls the signaling pathway. We know that after the
tyrosine kinase reaction, serine-threonine kinases take
over along the signaling route. It is thus highly probable
that serine-threonine phosphatases will counteract the
kinases and limit the intensity of the insulin or insulin
like signals. One of the phosph a t a s e si n v o l v e di sP P 2 A ,
itself the target of DNA viral oncogenes (Polyoma or
SV40 antigens react with PP2A subunits and cause
tumors). We found a possible link between the PP2A
phosphatase brake and choline in works on Alzheimer’s
disease [26]. Indeed, the catalytic C subunit of PP2A is
associated to a structural subunit A. When C receives a
methyle, the dimer recruits a regulatory subunit B. The
trimer then targets specific proteins that are depho-
sphorylated [27]. In Alzheimer’s disease, the poor
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homocysteine in the blood [26]. The result of the PP2A
methylation failure is a hyperphosphorylation of Tau
protein and the formation of tangles in the brain. Tau
protein is involved in tubulin polymerization, controlling
axonal flow but also the mitotic spindle. It is thus possi-
ble that choline, via SAM, methylates PP2A, which is
targeted toward the serine-threonine kinases that are
counteracted along the insulin-signaling pathway. The
choline dependent methylation of PP2A is the brake, the
“antidote”, which limits “the poison” resulting from an
excess of insulin signaling. Moreover, it seems that cho-
line deficiency is involved in the L to M2 transition of
PK isoenzymes [28].
3. Cellular distribution of PP2A
In fact, the negative regulation of Ras/MAP kinase sig-
nals mediated by PP2A phosphatase seems to be com-
plex. The serine-threonine phosphatase does more than
simply counteracting kinases; it binds to the intermedi-
ate Shc protein on the signaling cascade, which is inhib-
ited [29]. The targeting of PP2A towards proteins of the
signaling pathway depends of the assembly of the differ-
ent holoenzymes. The carboxyl methylation of C-term-
inal leucine 309 of the catalytic C unit, permits to a
dimeric form made of C and a structural unit A, to
recruit one of the many regulatory units B, giving a
great diversity of possible enzymes and effects. The dif-
ferent methylated ABC trimers would then find specific
targets. It is consequently essential to have more infor-
mation on methyl transferases and methyl esterases that
control the assembly or disassembly of PP2A trimeric
forms.
A specific carboxyl methyltransferase for PP2A [30]
was purified and shown to be essential for normal pro-
gression through mitosis [31]. In addition, a specific
methylesterase that demethylates PP2A has been puri-
fied [32]. Is seems that the methyl esterase cancels the
action of PP2A, on signaling kinases that increase in
glioma [33]. Evidently, the cellular localization of the
methyl transferase (LCMT-1) and the phosphatase
methyl esterase (PME-1) are crucial for controlling
PP2A methylation and targeting. Apparently, LCMT-1
mainly localizes to the cytoplasm and not in the
nucleus, where PME-1 is present, and the latter har-
bors a nuclear localization signal [34]. From these
observations, one may suggest that PP2A gets its
methyles in the cytoplasm and regulates the tyrosine
kinase-signaling pathway, attenuating its effects. A
methylation deficit should then decrease the methyla-
tion of PP2A and boost the mitotic insulin signals as
discussed above for choline deficiency, steatosis and
hepatoma. At the nucleus, where PME-1 is present, it
will remove the methyl, from PP2A, favoring the
formation of dimeric AC species that have different
targets, presumably proteins involved in the cell cycle.
It is interesting to quote here the structural mechan-
ism associated to the demethylation of PP2A. The
crystal structures of PME-1 alone or in complex with
PP2A dimeric core was reported [35] PME-1 binds
directly to the active site of PP2A and this rearranges
the catalytic triad of PME-1 into an active conforma-
tion that should demethylate PP2A, but this also seems
to evict a manganese required for the phosphatase
activity. Hence, demethylation and inactivation would
take place in parallel, blocking mitotic actions. How-
ever, another player is here involved, the so-called
PTPA protein, which is a PP2A phosphatase activator.
Apparently, this activator is a new type of cis/trans of
prolyl isomerase, acting on Pro190 of the catalytic C
unit isomerized in presence of Mg-ATP [36], which
would then cancel the inactivation mediated by PME-
1. Following the PTPA action, the demethylated phos-
phatase would become active again in the nucleus, and
stimulate cell cycle proteins [37,38] inducing mitosis.
Unfortunately, the ligand of this new prolyl isomerase
is still unknown. Moreover, we have to consider that
other enzymes such as cytochrome P450 have also
demethylation properties.
In spite of deficient methylations and choline dehydro-
genase pathway, tumor cells display an enhanced choline
kinase activity, associated to a parallel synthesis of
lecithin and triglycerides.
The hypothesis to consider is that triglycerides change
the fate of methylated PP2A, by targeting it to the
nucleus, there a methylesterase demethylates it; the
phosphatase attacks new targets such as cell cycle pro-
teins, inducing mitosis. Moreover, the phosphatase
action on nuclear membrane proteins may render the
nuclear membrane permeable to SAM the general
methyl donor; promoters get methylated inducing epige-
netic changes.
The relative decrease of methylated PP2A in the cyto-
s o l ,n o to n l yc a n c e l st h eb r a k eo v e rt h es i g n a l i n g
kinases, but also favors the inactivation of PK and PDH,
which remain phosphorylated, contributing to the meta-
bolic anomaly of tumor cells.
In order to prevent tumors, one should then favor the
methylation route rather than the phosphorylation route
for choline metabolism. This would decrease triglycer-
ides, promote the methylation of PP2A and keep it in
the cytosol, reestablishing the brake over signaling
kinases. Moreover, PK, and PDH would become active
after the phosphatase action. One would also gain to
inhibit their kinases as recently done with dichloroace-
tate for PDH kinase [17]. The nuclear or cytosolic tar-
geting of PP2A isoforms is a hypothesis also inspired by
several works [34,36-38].
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We know that the transition from fetal to adult hemo-
globin, with a lower oxygen affinity, would repeat the
phylogenic adaptation of “aquatic creatures” to breath in
air and live on land. Many adequate “adult proteins”
replace their fetal isoform: muscle proteins utrophine,
switches to dystrophine; enzymes such as embryonic M2
PK [39] is replaced by M1. Hypoxic conditions seem to
trigger back the expression of the fetal gene packet via
HIF1-Von-Hippel signals. The mechanism would
depend of a double switch since not all fetal genes
become active after hypoxia. First, the histones have to
be in an acetylated form, opening the way to transcrip-
tion factors, this depends either of histone deacetylase
(HDAC) inhibition or of histone acetyltransferase
(HAT) activation, and represents the main switch. Sec-
ond, a more specific switch must be open, indicating the
adult/fetal gene couple concerned, or more generally the
isoform of a given gene that is more adapted to the spe-
cific situation. When the adult gene mutates, an
unbound ligand may indeed indicate, directly or indir-
ectly, the particular fetal copy gene to reactivate [40]. In
anoxia, lactate is more difficult to release against its
external gradient, leading to a cytosolic increase of up-
stream glycolytic products, 3P glycerate or others. These
products may then be a second signal controlling the
specific switch for triggering the expression of fetal
genes, such as fetal hemoglobin or the embryonic M2
PK; this takes place if histones (main switch) are in an
acetylated form. This is the case if HAT is active in
tumor cells, in spite of the decrease of butyrate a HDAC
inhibitor. In tumor cells, one finds hypermethylated
regions, in which HDAC activity silences a set of genes
and hypomethylated parts in which HAT activates other
genes.
III. Growth hormone-IGF actions, the control of
asymmetrical mitosis
When IGF - Growth hormone operate, the fatty acid
source of acetyl CoA takes over. Indeed, GH stimulates
a triglyceride lipase in adipocytes, increasing the release
of fatty acids and their b oxidation. In parallel, GH
would close the glycolytic source of acetyl CoA, perhaps
inhibiting the hexokinase interaction with the mitochon-
drial ANT site. This effect, which renders apoptosis pos-
sible, does not occur in tumor cells. GH mobilizes the
fatty acid source of acetyl CoA from adipocytes, which
should help the formation of ketone bodies, but since
citrate synthase activity is elevated in tumors, ketone
bodies do not form. Hence, butyrate cannot inhibit his-
tone deacetylase (HDAC), the enzyme cuts acetylated
histone tails, this will silence several genes like PETEN,
P53, or methylase inhibitory genes. It is probable that
the IGFBP gene gets silent as well. IGFBP is a protein
that binds IGF with high affinity and controls its effects
[41]. In parallel, GH hormone induces in the liver, the
synthesis and release of insulin like growth factor (IGF).
The latter, activates like insulin, the IGF-tyrosine kinase
receptors (IGFR), triggering the MAP kinase-ERK mito-
genic signal. The surface distribution of IGF-IGFR may
determine if a cell is sterile or endowed with a mitotic
potential. We propose that this distribution depends of
IGFBP; suppose that a cell starting mitosis secretes
IGFBP at one pole, and that IGFBP binds to the extra-
cellular matrix, forming patches of IGFBP. The patch
may attract the IGF-IGFR complex by a capping pro-
cess. The daughter cell that inherits the IGFR receptor
patch becomes a stem cell, while the cell poor in IGFR
will be sterile and follow the differentiation program.
This does not mean that the sterile daughter cell, at
rest in the Go phase, cannot exit and divide again; this
would require a reactivation of IGFR receptor genes in
order to build up again the membrane concentration of
IGFR.
IV. Compounds for correcting tumor metabolism
The figure 1 indicates interrupted and enhanced meta-
bolic pathways in tumor cells.
In table 1, the numbered pathways represent possible
therapeutic targets; they cover several enzymes. When
t h ea c t i v i t yo ft h ep a t h w a yi si n c r e a s e d ,o n em a yg i v e
inhibitors; when the activity of the pathway decreases,
we propose possible activators.
V. Cancer prevention, immune destruction of
tumor cells
1. A preventive cure
André Gernez [82-84] applied for the first time the stem
cell concept to cancer and neurological diseases. “He
compared tissues to colonies of bees in which, only the
queens renew the colony, while most bees are sterile
workers”. For preventing cancer, he imagined an annual
cure, which did not receive much attention. It consists
of three points: first a fasting period once a year, “this is
recommended by most religions”, second one should eat
more fruits, vegetables, less meat, consume products
rich in magnesium, vitamins C, E, selenium, this is now
currently accepted. The third point is more difficult to
apply, without testing it on animal models. It aims to
kill once a year eventual tumor cells, by giving for a few
days an anti-mitotic, colchicine for example. Gernez
mentions that chloral, anciently used for treating mental
patients, also protected them from cancer, because it
has anti-mitotic properties. The idea being to kill the
very first tumor cells that eventually appear, and if
missed the first year, one would catch them the next
year etc... How can we explain the possible prevention?
The first point is evident, fasting increases ketone bodies
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inhibitor, this keeps histone tails acetylated, which can-
cels the silencing of several genes starting the tumor
process. The second part of the procedure takes advan-
tage of the anti-inflammatory properties of flavonoids
found in fruits and vegetables. Flavonoids cancel the
effects of hypoxia on the expression of a set of genes:
cyclooxygenase (COX), VEGF, NOsynthase, glycolytic
enzymes, induction of fetal genes. Recall that fetal M2
PK expression is a typical feature of tumor cells. We
know the anti-tumor effect of avastin and anti VEGF
antibodies. The anti-cancer properties of ‘non-steroidal
anti-inflammatory drugs,’’ NSAIDS, results from the
inhibition of COX decreasing pro-inflammatory prosta-
noids. Moreover, magnesium may inhibit calcium
dependent phospholipases forming arachidonic acid, the
prostanoid precursor and diacylglycerol (DAG) with
mitogenic effects. In addition, vitamins C, E, and sele-
nium, quench superoxides and peroxynitrite, formed by
a poor oxygen reduction during hypoxia. One may
strengthen this second line of protection with methyl
donors, folate, and vitamin B12. They would attenuate,
via methylated PP2A, the signaling kinases, activated by
insulin or IGF, and regulate the supply of glucose,
Table 1 Therapeutic targets
Targets Metabolic pathway Activity Drugs: inhibitors or activators References
1 Proteolysis/alanine/transaminase/pyruvate increased aminooxacetic, 2PAM, D alanine,
b chloro-L-alanine
[42,43]
2 Lactate dehydrogenase/pyruvate/lactate/NAD+
Malate dehydrogenase/OAA/malate/NAD+
Malic enzyme/malate/pyruvate/lactate/NAD+
increased
increased
increased
Br pyruvate, gossypol
D malate, humic acid
D malate
[44-46]
3 Glycolysis increased mannoheptulose, lodinamineepalresta, citrate [47-49]
4 PEP carboxykinase/PEP/OAA
Pyruvate carboxylase/pyruvate/OAA
increased
decreased
Cl-PEP, b sulphopyruvate
3-hydroxybutyrate (ketone bodies will activate)
[50,51]
[52]
5 Pyruvate kinase (M2 bottleneck)/PEP/pyruvate
Pyruvate dehydrogenase/pyruvate/acetylCoA
decreased
decreased
dihydroxyphenylethanol, polyethylene - glycol
lipoic acid, kinase inhibitors (dichloroacetate,
2-chloropropionate) or PP2A agonists (xylulose5P, B12,
choline)
[53-55]
[16,17]
6 Lipolytic fatty acid source of acetyl CoA
Carnitine transporter
increased niacine, Growth hormone inhibitors
Avoid oxfenicine or levofloxacin
[56,57]
7 Citrate synthase (OAA+ acetylCoA)/citrate increased Dserine, fluoroacetylCoA, carboxymethyl-CoA,
citrate (via product inhibition), capsaicine (via electron
transport inhibition and NADH increase)
[13]
8 ATPcitrate lyase citrate/OAA+acetylCoA
Triglycerides synthesis via acetyl CoA
Other OAA sources
increased
increased
increased
hydroxycitrate, fluorocitrate
xanthohumol (removes triglycerides)
D malate
[58]
[59]
9 Choline dehydrogenase/methylation/lipotropic
Choline kinase/phosphorylcholine/lecithin
decreased
increased
choline
miltefosin, farnesol
[60,61]
10 PP2A methylation (it counteracts signaling and
enzyme kinases)
decreased betaine, folate, B12, trimethylglycine (via SAM)
11 Histone deacetylase (gene silencing) increased butyrate, valproate, benzamide, trichostatin [62]
12 Cytochrome P450 demethylase (hypomethylated
promoters)HAT/hexokinase expression
Histone acetylase
increased
increased
ketonazole, bergamottin, quinine
anacardic acid, garcinol, curcumine
[63-67]
[66,67]
13 Tyrosine kinase-signaling route (MAP kin, PI3 kin,
PLCg)
increased imatinib mésilate (glivec chemotherapy)
14,15,
16
GH-IGF
IGFBP
increased
decreased
octreotide, pegvisomant
apigenin, casodex, omeprazol
[68-70]
17 Arginine dependency increased arginine deprivation diet,
pegylated arginine deiminase
[18-20]
[71-73]
18 Arginase/arginine/ornithine increased norvaline, N-omega-hydroxy-nor-arginine, boroargininre [74-76]
19 Polyamine pathway:
Ornithine decarboxylase/putrescine
SAM decarboxylase
increased DFMO (2-difluoromethylornithine),
MGBG methylglyoxal bis (guanylhydrazone),
4-amidinoindan-1one-2’-amidinhydrazone(alfa-
fluoromethylhistidine)
[77-79]
20 Glutaminase/glutamate increased DON(6-diazo-5-oxo-l-norleucine),
riluzole, naftazone
[80].
21 Argininosuccinate synthetase decreased troglitazone [81]
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Page 8 of 12anabolism and mitosis. The third point deserves addi-
tional experiments. The hypothesis is that tumor cells
appear frequently, but the immune surveillance con-
stantly eliminates them. If the immune surveillance fails,
an anti-mitotic would kill once a year, tumor cells
before they reach a critical mass. This third point of the
procedure would back-up the immune surveillance
when it fails, but deserves an evaluation.
2. The immune surveillance
Tumor cells or virus-invaded cells would display lower
MHC-1 levels, the major histocompatibility complex,
which is a self-recognition device. The consequence of
the MHC-1 decrease is to trigger the “Natural killer”
(NK) immune protection, because MHC-1 stops neutra-
lizing receptors (KIR) on NK cells, which triggers the
release of perforines by NK cells. The perforines kill
cells poor in MHC-1. Well, an up-regulation of Insulin
or IGF signals decreases MHC-1, and may then trigger
the NK protection [85], if such a protection fails then
tumor cells may survive...
The NK protection is activated by leucotriene LTB4
formed by lipoxygenase, and inhibited by the fever pros-
taglandin PGE2 formed by cycloxygenase [86]. Hence,
inhibitors of PGE2 and cycloxygenase trigger the NK
protection; this is an effect of non-steroid anti-inflamma-
tory drugs (NSAIDS) aspirin, ibuprofen, or of some his-
tone acetylase (HAT) inhibitors (curcumin, anacardic
acid garcinol etc...). It is also particularly interesting to
increase serotonin (5HT) that neutralizes the inhibition
of NK cells by PGE2. Echinacea extracts [87]; 5HT
uptake inhibitors (St John’s Wort tea, prozac, melato-
nine) [88] boost the release of 5HT from platelets, parti-
cularly if platelets are full of 5HT before reaching the
site. A substance P antagonist (aprepitan) [89] avoids
their premature degranulation). Finally 5HT can be pre-
served from its enzymatic conversion into quinolinic acid
by inhibiting indoleamine,2,3-dioxygenase with exigua-
mine or 1-methytryptophane [90,91]. Echinacea, melato-
nin, 5HT uptake inhibitors, substance P antagonists, and
HAT inhibitors [66,67,92,93] boost NK mediated protec-
tion against eventual tumor cell, or viral infections.
VI. A Possible sequential plural-therapy
As a complement to radiotherapies or chemotherapies,
we propose to try, after validating it on animal models a
sequential metabolic therapy. 1- Inhibit alanine transa-
minase, glutaminase, ornithine decarboxylase, arginase;
and decrease alanine, glutamine, arginine, supplies. 2-
Open PK and PDH bottlenecks (enzyme kinase inhibi-
tion and PP2A phosphatase activation by methylation
helpers) 3- Close citrate synthase, ATP citrate lyase,
increase the NADH mitochondrial potential. 4- Decrease
GH/IGF [94] and “tyrosine kinase receptor” signals. 5-
Cancel epigenetic changes using HDAC inhibitors and
then HAT inhibition. 6- Boost immune NK protection.
In this review, we have collected observations on
tumor cell metabolism obtained by many laboratories
working on cancer for the past 80 years. When we find
that choline related methylations protect from liver can-
cer, that PP2A methylations controls the Tyrosine
kinase oncogenic signals, activated by IGF-GH it seemed
logic to establish a link between these observations even
if they were not obtained simultaneously. The impres-
sion is that the link we make is perhaps artificial. How-
ever, a reference for all the experimental observations is
given. The link between them is the interpretation we
propose. This model has inspired our recent works, and
convergent interpretations from other laboratories sup-
port some of the model predictions. See for example
reference [95] suggesting a therapeutic approach with
multiple drugs acting on glycolysis. Additional works
target with drugs this metabolic transformation of
tumor cells [96] and manipulate for example a ketoglu-
tarate dehydrogenase [97] an enzyme similar to PDH,
which is less active in tumor cells as indicated in the
model. Other laboratories attack the increased glycolysis
with bromopyruvate as we also suggest [98]. As for the
spectacular effects of citrate and isocitrate [99,100] or
octreotide and capsaicine that the model predicts, they
may find a therapeutic application beneficial to patients
as shown by experiments on animals. Finally, the recent
discovery of a population of Dwarfs with no GH recep-
tors, which do not develop cancers [101], illustrates the
GH/IGF prediction, establishing a link between ancient
and recent biochemical observations on tumors. By add-
ing octreotide a somatostatin analogue, to the lipoic
acid isocitrate mixture, our recent results (in press)
seem to validate the presented model.
Conclusion: The origin of Cancers by means of
metabolic selection
The disruption of cells by internal or external com-
pounds, releases substrates stimulating the tyrosine
kinase signals for anabolism proliferation and stem cell
repair, like for most oncogenes. If such signals are not
limited, there is a parallel blockade of key metabolic
enzymes by activated kinases or inhibited phosphatases.
The result is a metabolism typical of tumor cells, which
gives them a selective advantage; stabilized by epigenetic
changes. A proliferation process, in which the two
daughter cells divide, increases the tumor mass at the
detriment of the body. Inevitable mutations follow,
selecting the most robust tumor cells... We only hope
that a non-toxic mixture will bring back to normality
cells when they acquire the selective metabolic advan-
tage, which leads them to cancer, this mixture may
back-up current cancer therapies.
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